<!DOCTYPE html>
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
	<meta name="viewport"content="target-densitydpi=device-dpi, initial-scale=1.0,user-scalable=no"/>
	<link rel="stylesheet" type="text/css" href="../assets/css/style.css"/>
	<link rel="stylesheet" type="text/css" href="../assets/css/estilos.css"/>
	<link rel="stylesheet" type="text/css" href="../assets/css/flaticon.css"/>
	<script type="text/javascript" src="../assets/js/jquery.js"></script>
	<script type="text/javascript" src="../assets/js/functions.js"></script>
</head>
<body>
	<div id="contenedor">
		<div id="menu_slide">
			<div id="as" class="fonts_i"><i class="flaticon-text162"></i></div>
			<div class="fonts_i"><input type="range" id="slide" min="0" max="72" value="0"></div>
			<div id="am" class="fonts_i"><i class="flaticon-edit-text"></i></div>
		</div>
		<div id="btn_opciones"><i class="flaticon-font14 fonts"></i></div>
		<div id="menu_botones">
			<div class="menu_contenedor">
				<div id="btn_normal" class="botones-caja-lector"></div>
				<div id="btn_sepia" class="botones-caja-lector"></div>
				<div id="btn_noche" class="botones-caja-lector"></div>
			</div>
			<div class="menu_contenedor">
				<select id="select_font">
					<option value="arial">Arial</option>
					<option value="century">New Century</option>
					<option value="futura">Futura</option>
					<option value="gillsans">Gill Sans</option>
					<option value="RobotoLight">Roboto</option>
					<option value="timesNew">Times New Roman</option>
				</select>
			</div>
		</div>
		<div id="contenedor-texto">
			<h1 id="subtitulo">8. Treatment</h1>
			<p>
				<b>Currently, the best treatment to stop the progression of diabetic retinopathy is adequate glycemic control.<sup>11</sup></b>
				<br>
				<br>
				An adequate control of blood pressure and lipids has been linked to lower risk of DR and its progression.<sup>2,4</sup>
				<h3>DR treatment includes:</h3>
				<ul>
					<li><b>Laser photocoagulation (LFC):</b> is indicated in patients with severe nonproliferative DR, in proliferative DR and diabetic macular edema.<sup>4</sup> Laser photocoagulation performed timely stops and prevents the progression of proliferative DR in 90% of cases.<sup>4</sup> In patients with high-risk proliferative DR, laser therapy reduces by 50% the vision loss.<sup>4</sup> The following are complications of LFC: the loss of 1 line of visual acuity, difficulty in dark adaptation and color vision, decreased peripheral vision and increased laser scars.<sup>2</sup> </li>
					<li><b>Intravitreal medical therapy:</b> intravitreal therapy includes angiogenesis inhibitors (anti-VEGF) and intravitreal steroids.<sup>2</sup> In DR, hyperglycemia and hypoxic state increase the production of vascular endothelial growth factor (VEGF) to 30 times.<sup>2</sup> Antiangiogenic drugs (bevacizumab, ranibizumab and pegaptanib) block the receptor for these factors and can improve macular edema and reduce retinal neovascularization.<sup>4</sup> It is believed that corticosteroids restore blood retinal barrier, reduce the production of growth factors (VEGF) and inflammatory prostaglandins, leading to resorption of the exudate, increasing occludin and zonula occludens of endothelial cells; These are used for the treatment of diffuse macular edema.<sup>2</sup> Some of the complications of intravitreal injection include: increased intraocular pressure, acute endophthalmitis, pseudo-endophthalmitis, retinal detachment and cataract, among others.<sup>2</sup></li>
					<li><b>Surgical treatment, vitrectomy:</b> via <em>pars plana</em>, , with or without photocoagulation, aims to treat the complications of the DR, to stabilize the retina and maintain vision.<sup>2</sup></li>
    			</ul>
			</p>
		</div>
	</div>
</body>
</html>